Conference Slides

Day 1

Hormones and the fountain of youth
Adriane Fugh-Berman MD, Georgetown University Medical Center
Tony Scialli MD, George Washington University


The endangered normal: Does anyone escape a diagnosis?
Adriane Fugh-Berman MD, Georgetown University Medical Center


Demented patients and difficult behaviors
Tom Finucane MD, Johns Hopkins School of Medicine


How safe are we? Health Canada and drug safety
Joel Lexchin MD MSc, York University


The impact of pricing of specialty drugs on care, coverage... and just about everything else
Sharon Levine MD, Kaiser-Permanente


The high price of a "free" market: Medicines pricing in the US and beyond
Ruth Lopert MD, George Washington University


Getting better in light of political realities
Louis Jacques MD, ADVI


What are the rules of the road? FDA law and regulations for reviews of drug and biological practices
John Powers MD, George Washington University


Day 2

Managing chronic pain: A case study of the potential of comparative effectiveness research
Carolyn Clancy MD, Department of Veterans Affairs


The opioid addiction epidemic: How marketing and regulartory failure led to a public health crisis
Andrew Kolodny MD, Physicians for Responsible Opioid Prescribing


Hyperglycemia, sedentary obesity and complications of type 2 diabetes
Tom Finucane MD, Johns Hopkins School of Medicine


Should black box warnings for fluoroquinolones be revised: Is the bar set too high?
Charles Bennett MD PhD, University of South Carolina


The risks of newer anticoagulants: Sales vs safety
Thomas Moore, Institute for Safe Medication Practices


Researchers behaving badly: Misconduct in clinical trials
Charles Seife, New York University


Psychiatry under the influence: Institutional corruption and diagnostic and practice guidelines
Lisa Cosgrove PhD, University of Massachusetts-Boston


Changes in medical students' responses to drug company marketing
Frederick Sierles MD, Rosalind Franklin University of Medicine and Science